11
Total investments
0
Early stage
5
Mid stage
4
Late stage
9y
Years active
Portfolio
11 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor & Board Member
Feb 2025
DIAGNOLY is a pioneer in the application of computational physics methods powered by deep learning algorithms to the domain of obstetric ultrasound.
Our aim is to help clinicians to address problems related to the obstetric ultrasound by improving the fetal diagnostics and simplifying the decision making.
Our solutions precisely define fetal biometric key parameters and help diagnosticians with detection of prenatal pathologies and congenital defects from the earliest weeks of pregnancy.
Investor & Board Member
Jan 2025
HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.
Investor & Board Member
Sep 2024
SURGAR offers a unique solution of augmented reality for the surgery of mobile and deformable organs in laparoscopy.
Our goal is to help surgeons deliver high precision care by expanding the capabilities of minimally invasive surgery thanks to the visualization of the internal structures of the organs.
Our motto: Saving lives through better surgery!
Investor
Jan 2024
SamanTree Medical proposes a breakthrough innovation for checking complete tumor removal during surgery: the Histolog® Scanner. This novel imaging modality is a direct support during cancer surgery to achieve the common goal of improving patient quality of life by decreasing rates of re-operation.
The team is fully dedicated to bringing the Gold Standard in the operating room, enabling margin assessment, in real time, at the histological detail.
SamanTree Medical SA was founded in December 2014 and is a spin-off of the EPFL (Ecole Polytechnique Fédérale de Lausanne).
linktr.ee/SamanTree
Investor and Board Member
Jul 2022
Our housing marketplace allows seniors to rent their spare rooms and make extra money while co-living with younger people.
In a world where 27% of senior people suffer from loneliness and 17% of students stop their studies because they cannot afford to pay their rent, intergenerational co-living can have tremendous positive impacts for both parties.
For a senior, hosting a student means:
- Having a companion at home
- Generating extra revenue
- Getting help for small tasks
- Building a meaningful relationship
- Living in their home for longera
For a student, co-living with a senior means:
- Accessing quality, affordable, study-friendly accommodation
- Building a meaningful relationship
- Having a sense of purpose and impact
The Club allows seniors to connect & bond with others while breaking the monotony of loneliness. Its the 1st mobile app built for (and with) seniors to help them boost their social life, 100% free of charge, by attending to activities, sharing interests in discussion groups, staying mentally active through daily challenges...
More to come...
Investor
Jun 2022
Pina Earth enables forest owners to participate in the voluntary carbon market by digitizing the manual certification process, aided by remote sensing and artificial intelligence.
Investor & Board Member
Apr 2022
Greenly is on a mission to democratize access to science-backed climate intelligence, transforming sustainability from a compliance burden into a strategic competitive advantage.
In a world where sustainability once meant costly consultants, manual data entry, and static PDF reports, Greenly makes climate action accessible, precise, and actionable for everyone: from SMEs to global enterprises.
Our all-in-one sustainability suite centralizes everything from carbon management and LCAs to ESG & CSRD reporting, backed by 4000+ delivered GHG reports, 10+ ESG frameworks, and a supplier platform engaging over 5,000 partners. Trusted by 3,500 clients in 25 countries, Greenly combines science-backed precision, with access to 300k+ emission factors and methodologies aligned with the GHG Protocol, ISO, and SBTi—with expert guidance from 70+ climate professionals, ensuring every company builds credible strategies and becomes smarter about climate as they go.
Designed with efficient tech and intuitive UX, Greenly streamlines sustainability operations with integrations across 100+ softwares, automated quality controls, and real-time data visualizations, earning us top ratings (4.9 G2, 4.8 Capterra, 4.6 Trustpilot).
Greenly empowers companies to own their climate expertise in-house and collectively drive impact toward our bold goal: avoiding 1 billion tons of CO₂ by 2030.
Investor
Feb 2022
At Synapse Medicine, we believe in medication success, and are dedicated to creating the technology that makes it possible for everyone.
To achieve this goal, we have built an extensive global knowledge base for medication using algorithms to ensure the most reliable, up-to-date data. On the front-end, Synapse Medicine provides a SaaS platform and UI components that are used to prescribe, dispense, and manage medications across the entire patient journey.
Synapse is working with world-leading hospitals and digital health companies in the United States, Europe, and Japan to transform today’s medication regimens into tomorrow’s medication success.
Investor
Jan 2022
Were hiring worldwide!
https://wandercraft.welcomekit.co/
At Wandercraft, we believe movement is freedom. Since 2012, our mission has been simple but bold: restore mobility where it’s been lost, and expand what’s possible with robotics that move like people do.
We see robotics as the ultimate partners—machines that can do what humans cannot, or should not, do. That means giving back the ability to walk to someone with a spinal cord injury, or stepping in on a factory floor where work is too heavy, repetitive, or hazardous.
We pioneered the world’s first self-balancing exoskeleton—technology that doesn’t rely on crutches or walkers, but lets people stand and walk freely. Today, our work goes beyond healthcare. From rehabilitation centers to factory floors, and soon into homes and communities, we’re shaping a future where humans and robots move forward together.
Our technology, powered by physical AI and 30+ patents, is life-tested in the most demanding environments: real people, real steps, real work.
Meet our devices:
Atalante X – A self-balancing exoskeleton enabling hundreds of patients with mobility disabilities to take over 1 million steps per month in 100+ leading hospitals and research centers worldwide. It is designed to promote upright posture, cardiovascular health, neuroplasticity, and—most importantly—upright independence.
Eve – The world’s first self-balancing exoskeleton for personal use. Designed for daily life, Eve enables individuals with severe mobility impairments to walk hands-free at home and outdoors. Currently in U.S. clinical trials, Eve is expected to launch in 2026.
Calvin-40 – Our first industrial humanoid robot. Autonomous and voice-operated, Calvin-40 is built to take on physically demanding or hazardous tasks in non-ergonomic environments. Based on the same platform as our exoskeletons, Calvin is already hard at work with Renault Group and more.
Investor & Board Member
Jul 2021
Notre mission chez Lifeaz est de permettre à tous les citoyens et à toutes les entreprises d’être capables de sauver une vie. Pour cela, nous avons développé Clark, le 1er défibrillateur français et connecté, conçu pour être déployable absolument partout : dans les entreprises et les lieux publics bien sûr, et au domicile des particuliers ⚡️ Nous vous sensibilisons aussi aux gestes qui sauvent, afin que vous et vos proches osiez intervenir en cas d’arrêt cardiaque !
Chaque année en France, 50 000 personnes meurent dun arrêt cardiaque et nous sommes tous concerné(e)s. Le taux de survie est de 5% car il faut agir dans les 4 premières minutes alors que les secours mettent 15 minutes pour venir. Il faut agir avant leur arrivée... 80% des arrêts cardiaques ont lieu à domicile ou sur le lieu de travail, et dans 70% des cas, un témoin est présent et peut changer les choses avec un défibrillateur et des gestes simples 💙
À ce jour, 10 000 familles et entreprises sont équipées de notre défibrillateur et plus de 25 vies ont pu être sauvées, d’une petite fille de 3 ans à une femme de 83 ans. Ce nest que le début, nous ne comptons pas nous arrêter là ! Ensemble, sauvons des milliers de vies 🚀
Pour plus d’informations, abonnez-vous à notre page Lifeaz !
Et si vous souhaitez rejoindre léquipe, rendez-vous sur : https://www.welcometothejungle.com/fr/companies/lifeaz
Investor and Board Observer
Sep 2017
Olyos est un acteur international de la nutrition et santé naturelle. Le groupe à l’ADN pharmaceutique compte plus de 450 salariés, répartis au sein des 4 entités suivantes : EA Pharma (France), Drasanvi (Espagne) Stardea (Italie) et W Group (USA). Son siège social est basé à Mougins (France). Olyos Group, cest également 5 marques globales : Granions, Labcatal, Eafit, Drasanvi et Stardea.
Experience · 19 entries
All (19)
Investments (11)
Founder (1)
Board (7)
2025
Investor & Board Member
Feb 2025
DIAGNOLY is a pioneer in the application of computational physics methods powered by deep learning algorithms to the domain of obstetric ultrasound.
Our aim is to help clinicians to address problems related to the obstetric ultrasound by improving the fetal diagnostics and simplifying the decision making.
Our solutions precisely define fetal biometric key parameters and help diagnosticians with detection of prenatal pathologies and congenital defects from the earliest weeks of pregnancy.
Investor & Board Member
Jan 2025
HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.
2024
Investor & Board Member
Sep 2024
SURGAR offers a unique solution of augmented reality for the surgery of mobile and deformable organs in laparoscopy.
Our goal is to help surgeons deliver high precision care by expanding the capabilities of minimally invasive surgery thanks to the visualization of the internal structures of the organs.
Our motto: Saving lives through better surgery!
Investor
Jan 2024
SamanTree Medical proposes a breakthrough innovation for checking complete tumor removal during surgery: the Histolog® Scanner. This novel imaging modality is a direct support during cancer surgery to achieve the common goal of improving patient quality of life by decreasing rates of re-operation.
The team is fully dedicated to bringing the Gold Standard in the operating room, enabling margin assessment, in real time, at the histological detail.
SamanTree Medical SA was founded in December 2014 and is a spin-off of the EPFL (Ecole Polytechnique Fédérale de Lausanne).
linktr.ee/SamanTree
2022
CDL Mentor - Climate
Aug 2022
Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.
The nine-month program employs an objectives-based mentoring process to enhance the performance of technical founders who learn from the insights of experienced entrepreneurs, with the goal of maximizing equity-value creation.
Founded by Professor Ajay Agrawal in 2012 at the University of Toronto’s Rotman School of Management, the program has expanded and now has 11 sites across six countries: Toronto, Vancouver, Calgary, Montreal, Halifax, Paris, Madison, Seattle, Estonia, Berlin, and Melbourne.
The program combines 5 elements to help companies transition from science projects to scalable and financeable companies:
- An emphasis on objective-setting, helping companies focus on what’s most important to their business
- Focused mentorship from experienced entrepreneurs who have founded, led, and sold significant tech companies
- Technical advice from world-leading scientists, engineers, and economists
- Hands-on support from top business students, who embed within the company to provide business support
- Opportunities to raise capital, including angels and VCs from Europe and North America
The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over CAD $35 billion in equity value.
Show all 19 entries ↓
Investment activity
2017–2025 · 11 investments
Recent (last 2 years)Earlier
